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license (http://creativeconsist of multiple cognitive domains as they may provide greater sensitivity to detect b-amyloid
(Ab)–related cognitive decline than episodic memory (EM) composite scores alone. However, this
has never been empirically tested. We compared the rate of cognitive decline associated with high
Ab (Ab1) and very high Ab (Ab11) in cognitively normal (CN) older adults on three multidomain
cognitive composite scores and one single-domain (EM) composite score.
Methods: CN older adults (n5 423) underwent Ab neuroimaging and completed neuropsycholog-
ical assessments at baseline, and at 18-, 36-, 54-, and 72-month follow-ups. Four cognitive composite
scores were computed: the ADCS-PACC (ADCS-Preclinical Alzheimer Cognitive Composite),
ADCS-PACC without the inclusion of the mini-mental state examination (MMSE), an EM compos-
ite, and the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older
adults (ZAVEN) composite.
Results: Compared with Ab1 CN older adults, Ab11 CN older adults showed faster rates of
decline across all cognitive composites, with the largest decline observed for ZAVEN composite
(d5 1.07). Similarly, compared with Ab2 CN older adults, Ab1 CN older adults also showed faster
rates of cognitive decline, but only for the ADCS-PACC no MMSE (d 5 0.43), EM (d 5 0.53), and
ZAVEN (d 5 0.50) composites.
Discussion: Ab-related cognitive decline is best detected using validated neuropsychological
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Ab-related cognitive decline between Ab1 and Ab11 CN older adults.
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There is now consensus that in cognitively normal (CN)
older adults, high levels of b-amyloid (Ab), assessed using
Ab imaging or cerebrospinal fluid sampling, represent the
preclinical stage of Alzheimer’s disease (AD) [1–3].
Multiple prospective studies have shown that substantial
decline in cognitive function occurs in Ab1 CN older
adults over periods of 6–54 months, even in the absence of
any progression to clinically recognizable mild cognitive
impairment (MCI) or AD [4–7]. In Ab1 CN older adults,
this cognitive decline is associated with faster
accumulation of Ab [1,8] as well as greater loss of
hippocampal volume and decreased levels of brain
metabolism [9,10]. Although there is general agreement
that Ab levels should be classified as low (Ab2) or high
(Ab1) [11,12], a recent analysis from our group using a
two-graph receiver operator curve (ROC) analysis of Ab
levels in the Australian Imaging, Biomarkers, and Lifestyle
(AIBL) cohort indicated that a standardized uptake value ra-
tio (SUVR) of 1.9 provided the optimal cut point for distinc-
tion of Ab levels in people with dementia from age-matched
healthy controls [2]. Hence, when Ab levels in CN older
adults were classified additionally as being high (Ab1:
SUVR 1.50–1.90) or very high (Ab11: SUVR .1.90),
onlyAb11CN individuals showed increased rates of cogni-
tive decline relative to Ab2 CN older adults. In fact, CN
older adults with Ab1 did not show cognitive decline over
a 36-month period [5]. Furthermore, in CN older adults,
Ab11 was associated with a higher risk of progression to
MCI or AD compared with CN adults with Ab1 [2]. Taken
together, these data suggest that it may be prudent to consider
Ab burden beyond a single positive/negative category in the
design of clinical trials for new anti-Ab therapies [13,14].
An important consideration in measuring the effects of Ab
in clinical research studies and clinical trials of preclinical AD
is the method used to operationalize a cognitive end point.
Currently, there is consensus that the composite measures
used commonly to characterize disease progression in patients
with prodromal AD or dementia, such as the mini-mental sta-
tus examination (MMSE), the Alzheimer’s Disease Assess-
ment Scale-Cognitive Subscale (ADAS-Cog), or the clinical
dementia rating (CDR) scale, are not appropriate for use in
CN older adults because data distributions from these scales
are characterized by restricted range of possible scores, ceiling
effects, and negative skew, thus rendering it insensitive to sub-
tle changes [15–17]. As such, research into cognitive declinein preclinical AD uses composite outcome measures based
on data from standardized neuropsychological tests, such as
tests of episodic memory and executive function, on which
performance is most affected in this early disease stage
[5,18,19].
Multiple studies from different natural history cohorts
indicate that in preclinical AD, episodic memory provides
a highly reliable and sensitive index of Ab-related cognitive
decline [3–5,20]. Therefore, episodic memory (EM)
composite scores provide a sound comparator for
determining the extent to which newer composite
measures based on tests that measure cognitive domains
other than episodic memory can yield any improved
sensitivity of Ab-related cognitive decline. Some
composite scores developed for preclinical AD include
measures of additional cognitive domains on the basis that
their inclusion may provide greater sensitivity to detect
Ab-related cognitive decline than EM composite scores
alone [21]. For example, the recently validated cognitive
composite for the Anti-Amyloid treatment in Asymptomatic
Alzheimer’s disease (A4) trial, the Alzheimer Disease Coop-
erative Study (ADCS) Preclinical Alzheimer Cognitive
Composite (ADCS-PACC), emphasized measurement of
specific cognitive domains, rather than specifying the tests
used to operationally define those domains. The ADCS-
PACC combines measures of episodic memory (e.g., mea-
sures of list learning such as the Free and Cued Selective Re-
minding Test [FCSRT] or the California Verbal Learning
Test, Second Edition [CVLT-II] and measures of paragraph
recall such as the Wechsler Memory Scale Logical Memory
delayed recall [LM-DR] or New York University Paragraph
Recall test), complex attention (e.g., the Wechsler Adult In-
telligence Scale-Revised Digit Symbol Substitution Test
[DSST] score), and a general cognitive screen (e.g., the
MMSE total score) [18]. Although each of the tests used
to define episodic memory and complex attention in the
ADCS-PACC have demonstrated sensitivity to cognitive
decline in early AD, the MMSE has not [16,17].
Therefore, its inclusion may reduce the sensitivity of the
ADCS-PACC because of its suboptimal metric characteris-
tics when its use is restricted to CN older adults (i.e., ceiling
effects, negative skew, poor test-retest reliability) [15–17].
An additional limitation of the ADCS-PACC is that it
does not include a measure of executive function when sub-
stantial Ab-related decline in this domain is also observed
reliably in preclinical AD, often to a greater extent than
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composite scores used in studies of preclinical ADmay have
increased sensitivity to drug effects and Ab-related cognitive
decline if they also included ameasure of executive function.
Consequently, the sensitivity of the ADCS-PACC to detect-
ing Ab-related cognitive decline in preclinical AD might be
improved if the MMSE was replaced with a measure of ex-
ecutive function (e.g., a measure of verbal fluency; [5]), so
that it will reflect primarily attention, verbal fluency, and
episodic memory. To address this possibility, we compared
the rate of cognitive decline associated with Ab1 and
Ab11 in CN adults using the ADCS-PACC, the ADCS-
PACC without the MMSE, an EM composite, and a compos-
ite score derived from neuropsychological tests of attention,
executive function, and episodic memory. The first hypothe-
sis was that cognitive decline in Ab11 CN older adults
would be greater than that in Ab1 CN older adults, which
would in turn be greater than in Ab2 CN older adults.
The second hypothesis was that composite scores that did
not include the MMSE would be more sensitive in detecting
Ab-related cognitive decline in Ab1 and Ab11 CN older
adults.2. Methods
2.1. Participants
Participants were recruited from a group of CN older
adults enrolled in the AIBL study, the recruitment of which
has been described previously [12,23]. Briefly, exclusion
criteria included schizophrenia; depression (15-item geri-
atric depression score 6); Parkinson’s disease; symptom-
atic stroke; uncontrolled diabetes; sleep apnea; and alcohol
use exceeding two standard drinks per day for women or
four per day for men. Participants underwent medical, psy-
chiatric, and neuropsychological assessments at baseline,
and 18-, 36-, 54-, and 72-month follow-ups [23]. At each
assessment, a clinical review panel considered all availableTable 1
Demographic and clinical characteristics of the sample by Ab status
Characteristics
CN Ab2 (n 5 326) CN A
n (%) or mean (SD) n (%)
Female sex 179 (54.9) 22
APOE ε4 genotype 64 (19.6) 19
Age 68.27 (5.95) 73.06
Premorbid IQ 108.27 (7.07) 109.18
GDS 0.92 (1.40) 0.76
HADS depression 2.61 (2.20) 2.97
HADS anxiety 4.26 (2.85) 4.76
CDR 0.03 (0.11) 0.08
CDR sum of boxes 0.04 (0.16) 0.05
MMSE 28.95 (1.14) 28.58
Abbreviations: Ab, b-amyloid; CN, cognitively normal; SD, standard deviation
anxiety and depression scale; CDR, clinical dementia rating scale; MMSE, mini-m
of Adult Reading.
NOTE. Bold values indicate statistical significance at P ,.001 level.medical, psychiatric, and neuropsychological information
to classify clinical status [23]. Clinical classification was
blinded to neuroimaging results. Group demographic and
clinical characteristics are shown in Table 1. The study
was approved by and complied with the regulations of three
institutional research and ethics committees [23]. All
participants provided written informed consent.2.2. Measures2.2.1. Neuroimaging and APOE genotyping
Fasted blood samples (80 mL) were collected from each
participant, of which 0.5 mL was sent to a clinical pathology
laboratory for APOE genotyping. Ab imaging with positron
emission tomography (PET) was conducted using either
11C-Pittsburgh Compound B (PiB), 18F-florbetapir, or 18F-
flutemetamol. PET methodology has been described in
detail previously [12,24,25]. A 30-minute acquisition was
started 40 minutes after injection of PiB, a 20-minute acqui-
sition was performed 50minutes after injection of florbetapir
and 90 minutes after injection of flutemetamol. For PiB-
PET, standardized uptake value (SUV) data were summed
and normalized to the cerebellar cortex SUV, resulting in a
region-to-cerebellar ratio termed SUVR. The whole cere-
bellum was the reference region for florbetapir [24], whereas
for flutemetamol, the reference region was the pons [25].
SUVRwas classified as either negative (Ab2), high positive
(Ab1), or very high positive (Ab11). For PiB, the usual 1.5
SUVR was used to discriminate between Ab2 and Ab1,
whereas a 1.9 SUVR obtained from a ROC curve analysis
was used as the optimal cut point to discriminate age-
matched CN older adults fromAD patients. Thus, this higher
SUVR cut point was used to discriminate between Ab11
(SUVR .1.9) and Ab1 (SUVR 1.5–1.9) [2]. Similarly,
for flutemetamol, SUVR thresholds of 0.61, 0.61–0.82,
and 0.82 were used to discriminate between Ab2, Ab1,b1 (n 5 33) CN Ab11 (n 5 64)
Por mean (SD) n (%) or mean (SD)
(66.7) 30 (46.9) .174
(57.6) 32 (50.0) .000
(7.13) 73.19 (7.41) .000
(7.75) 110.37 (6.62) .085
(1.17) 0.63 (1.03) .247
(2.87) 2.49 (2.59) .623
(2.77) 4.14 (2.95) .583
(0.22) 0.02 (0.11) .096
(0.15) 0.02 (0.11) .746
(1.25) 28.91 (1.18) .203
; APOE, apolipoprotein E; GDS, geriatric depression scale; HADS, hospital
ental state examination; premorbid IQ was assessed using the Wechsler Test
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olds used were 1.10, 1.10–1.29, and 1.29, respectively [2].
2.2.2. Cognitive composite scores
Cognitive composite scores were computed by standard-
izing outcome measures for each neuropsychological test on
each assessment using baseline mean and standard deviation
(SD) for the entire group. This yielded four cognitive com-
posite scores as follows: (1) the ADCS-PACCwas computed
as described previously [18], by averaging standardized
scores on measures of episodic memory (CVLT-II total
recall score and LM-DR score), attention (DSST score),
and the MMSE; (2) the ADCS-PACC no MMSE was
computed by averaging the standardized scores on the
CVLT-II total recall score, LM-DR, and DSST only; (3)
the AIBL EM composite was computed as described previ-
ously [5], by averaging standardized scores on the CVLT-II
delayed recall, LM-DR, and Rey Complex Figure Test de-
layed recall tasks; and (4) the Z-scores of Attention, Verbal
fluency, and Episodic memory for Nondemented older adults
(ZAVEN) composite was computed by averaging standard-
ized scores on measures of attention (DSST), executive
function (FAS), and episodic memory (CVLT-II total recall
and LM-DR).2.3. Data analysis
Data analyses proceeded in two steps. First, average mea-
sure intraclass correlation coefficients were used to compute
the test-retest reliability of each cognitive composite over the
five time points, and skew statistics were reported for each
composite at baseline. Second, for each cognitive composite
score, three planned comparisons were conducted using
repeated-measures linear mixed-effects models with
maximum likelihood estimation and an unstructured covari-
ance matrix. Linear mixed modeling was used because of
its ability to model both fixed and random effects, which ac-
counts for multiple sources of variability in longitudinal
studies. Additionally, both empirical and theoretical models
of AD show that once the threshold for Ab positivity
is reached, there is a linear trend in cognitive decline, neuro-Table 2
Effect of Ab group on cognitive decline over 72 months in CN older adults and gro
Ab group
Cognitive composite
Group Time Group! t
(df) F P (df) F P (df) F
EM (2437) 3.69 .03 (1365) 5.48 .00 (2364) 3.9
ADCS-PACC (2442) 5.95 .00 (1396) 21.80 .00 (2392) 20.
ADCS-PACC (no MMSE) (2441) 0.904 .02 (1380) 12.93 .00 (2378) 23.
ZAVEN (2435) 4.80 .01 (1377) 24.28 .00 (2375) 26.
Abbreviations: Ab, b-amyloid; CN, cognitively normal; SD, standard deviation
heimer Cognitive Composite; ADCS-PACC (no MMSE), ADCS Preclinical Alzh
amination; ZAVEN, Z-scores of Attention, Verbal fluency, and Episodic memory
NOTE. All models have been adjusted for age and APOE.degeneration, and Ab accumulation until a clinical diagnosis
of AD is reached [1,8,26]. In these analyses, group (Ab2,
Ab1, and Ab11), time, and group ! time interaction
were entered as fixed factors; participant as a random
factor; age and APOE ε4 status as covariates; and cognitive
composite score as the dependent variable. Within the
model, the magnitude of difference from the Ab2 group
was expressed using Cohen’s d.3. Results
3.1. Demographic and clinical characteristics
At baseline, there were statistically significant group dif-
ferences in age and APOE ε4 carriage (Table 1). As such,
these variables were entered as covariates in all subsequent
analyses. None of the other demographic or clinical charac-
teristics differed between groups. Participants across all
groups showed high levels of premorbid intelligence, low
levels of depressive and anxiety symptoms, and their cogni-
tive health was reflected in the low scores on the CDR and
high scores on the MMSE (Table 1).3.2. Test-retest reliability of cognitive composite scores
High test-retest reliability across the three assessment
time points was observed for the EM composite
(r 5 0.93, P , .001), the ADCS-PACC (r 5 0.92,
P , .001), the ADCS-PACC no MMSE (r 5 0.94,
P , .001), and the ZAVEN (r 5 0.96, P , .001). Data for
each composite were normally distributed, with skewness
of 20.28 (standard error [SE] 5 0.12) for EM, 20.36
(SE 5 0.12) for the ADCS-PACC, 20.09 (SE 5 0.13) for
ADCS-PACC no MMSE, and 20.16 for the ZAVEN
(SE 5 0.12).3.3. Effect of Ab levels on cognitive change in cognitive
composite scores
There were significant interactions between group and
time for all cognitive composite scores (Table 2). Group
mean slopes for each Ab/ε4 group for each compositeup mean (SD) of slope (rate of change) in each cognitive composite for each
ime CN Ab2 (n 5 326) CN Ab1 (n 5 33) CN Ab11 (n 5 64)
P Mean slope (SD) Mean slope (SD) Mean slope (SD)
4 .00 0.027 (0.163) 20.057 (0.125) 20.132 (0.131)
39 .00 0.002 (0.335) 20.082 (0.245) 20.205 (0.263)
68 .00 0.028 (0.165) 20.042 (0.126) 20.134 (0.133)
88 .00 0.014 (0.141) 20.055 (0.108) 20.133 (0.113)
; EM, episodic memory composite; ADCS-PACC; ADCS Preclinical Alz-
eimer Cognitive Composite without MMSE; MMSE, mini-mental state ex-
in Nondemented older adults.
Fig. 1. Magnitude of decline on each cognitive composite over 72 months
relative to the CN Ab2 group (error bars represent 95% CIs). Abbrevia-
tions: CN, cognitively normal; Ab, b-amyloid; CI, confidence interval;
ADCS-PACC, ADCS-Preclinical Alzheimer Cognitive Composite;
MMSE, mini-mental state examination; ZAVEN, Z-scores of Attention,
Verbal fluency, and Episodic memory in Nondemented older adults.
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with Ab2 CN older adults, Ab1 CN older adults showed
a faster rate of decline, but only on the ADCS-PACC no
MMSE, ZAVEN, and EM composites (Table 2), with these
differences moderate in magnitude (Fig. 1). Relative to
Ab1 CN older adults, Ab11 CN older adults showed a
significantly faster decline on all cognitive composites
(Table 2), with these differences also moderate in
magnitude (Fig. 1).4. Discussion
The results of this study supported the first hypothesis
that cognitive decline in Ab11 CN adults would be greater
than that in Ab1 CN adults, which would in turn be greater
than in Ab2 CN adults. Specifically, compared with Ab1
CN older adults, Ab11 CN older adults showed faster rates
of decline across all cognitive composite scores, with the
largest decline observed for the ZAVEN composite
(d 5 0.70; Table 2). Similarly, compared with Ab2 CN
older adults, Ab1 CN older adults also showed faster rates
of cognitive decline, but only for the EM and ZAVEN com-
posite scores (Table 2). We and others have typically group-
ed Ab levels into two categories (positive and negative) to
determine associations between Ab levels and cognitive
function [3,4,7,27]. However, we recently showed that
when SUVR distributions are further divided into Ab1
and Ab11, additional prognostic information can be
derived. Specifically, compared with Ab1 CN older
adults, Ab11 CN older adults have an increased risk of
progression to clinically classified MCI or AD, as well as
an increased rate of memory decline over a 36-month period
[2,5]. In accordance with our previous observations, results
of the present study suggest that the additional grouping ofSUVR distributions into two categories of abnormality can
improve understanding of the rate of Ab-related cognitive
decline in CN older adults.
The second hypothesis that composite scores that did not
include the MMSE would be more sensitive in detecting
Ab1-related cognitive decline in Ab1 older adults was
also supported. First for Ab11 CN older adults, the
ADCS-PACC provided the lowest sensitivity to Ab-related
change (d 5 20.64 in CN Ab11). Removing the MMSE
from the ADCS-PACC (i.e., the ADCS-PACC no MMSE)
increased this estimate of sensitivity substantially
(d 5 21.01 in CN Ab11). Adding a test of verbal fluency
to that for the CVLT-II, LM-DR, and DSST (i.e., ZAVEN)
resulted in similar sensitivity to that observed for the
ADCS-PACC no MMSE (d 5 21.07 in CN Ab11).
Furthermore, statistically significant differences between
Ab2 CN older adults and Ab1 CN older adults were
observed for all composites that did not include the
MMSE, that is the ADCS-PACC no MMSE (d 5 0.43),
ZAVEN (d 5 0.50), and EM composites (d 5 0.53), but
not the ADCS-PACC (d5 0.26). These results are consistent
with our previous reports that Ab11 in CN older adults is
associated with increased rates of decline in cognitive func-
tion [5]. However, although we have reported that Ab1 was
not associated with decline in cognitive function over a 36-
month period in CN older adults, the current results indicate
that over a 72-month period, Ab1 is associated with signif-
icant cognitive decline of a moderate magnitude in this pop-
ulation, albeit detectable only with composites that do not
include the MMSE.
The ADCS-PACC is an empirically derived cognitive
outcome measure developed for use in clinical trials of
novel anti-Ab therapies in preclinical AD [18]. One notable
characteristic of the ADCS-PACC was that it emphasized
the cognitive domains that should be included as opposed
to specifying which cognitive tests should operationalize
each domain. For example, in the validation study,
ADCS-PACC composites from different studies were based
on three different word list learning tasks (i.e., FCSRT,
CVLT-II, and the delayed word recall task from the
ADAS-Cog) and two different paragraph recall tasks (i.e.,
LM-DR and New York University paragraphs). Despite
this flexibility, we believe that there are two limitations to
the ADCS-PACC. The first is the inclusion of the MMSE,
and the second is the absence of a measure of executive
function. Hence, in the present study, we determined
whether replacing the MMSE with a measure of executive
function (e.g., the verbal fluency FAS task used in this
study) would increase the sensitivity of the cognitive com-
posite to Ab-related cognitive decline in CN older adults.
When we replaced the MMSE with this measure of execu-
tive function, the sensitivity of this composite score to de-
tecting Ab-related cognitive decline in both the Ab1 and
Ab11 CN groups increased beyond that observed for the
ADCS-PACC.
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of high Ab burden in CN older adults such that clinical trials
of anti-Ab therapies designed to halt or slow the progression
of AD are now being conducted in Ab1 CN older adults
[13,14,28]. These clinical trials have emphasized the
utility of a composite measure of cognitive function as
primary cognitive end points [18,19,28]. Although
experimental models have consistently demonstrated that
measures of EM or EM composites provide the most
sensitive indicator of Ab-related cognitive decline [3–5],
others have suggested that a multidomain cognitive
composite may provide even greater sensitivity to
detecting Ab-related cognitive decline [21]. The results of
our present study show that the EM composite was equally
sensitive as our multidomain cognitive composite (i.e.,
ZAVEN) in detecting cognitive decline associated with
both Ab1 and Ab11 in CN adults, and performed better
than the ADCS-PACC. However, given this equivalence,
the ZAVEN or ADCS-PACC no MMSE might be preferable
given that their coverage of cognitive domains other than
memory might make any change detected more clinically
relevant.
One assumption in the generation of the ZAVEN com-
posite measure was that inclusion of the MMSE in the
ADCS-PACC would limit its sensitivity to detecting Ab-
related cognitive decline. Interestingly, when the MMSE
was combined with scores from the neuropsychological
tests of EM and attention, no substantial skewness was
observed and estimates of test-retest reliability remained
high. However, it is notable that estimates of the SD associ-
ated with the mean rate of change on the ADCS-PACC for
each Ab subgroup was approximately twice that observed
for estimates of the SDs for Ab-related cognitive change
on the EM and ZAVEN composite scores (Table 2). Simi-
larly, the ADCS-PACC no MMSE yielded change scores
with much lower SDs across all groups and this resulted
in its improved sensitivity to Ab-related cognitive decline
(Table 2, Fig. 1).
The relatively lower sensitivity of theADCS-PACCdue to
the inclusion of the MMSE demonstrates the importance of
test selection in constructing composite scores as cognitive
end points in clinical research studies and clinical trials in
Ab1 CN older adults, that is, composite scores should
consist of measures of relevant cognitive domains that also
have good metric properties. Hence, if a measure of general
cognitive function was required in the ADCS-PACC, we
would recommend the inclusion of an instrument with suit-
ablemetric properties in CN older adults, such as, the demen-
tia rating scale-2 [29]. It is noteworthy that the cognitive
composite score developed by the Alzheimer’s Prevention
Initiative (API) trial also includes a subtest of the MMSE
(i.e., MMSE orientation to time subtest) [19]. On the basis
of the results of the present study, this composite may also
have some decreased sensitivity to detecting Ab-related
cognitive decline in CN older adults, compared with thesame composite without this MMSE item. Unfortunately,
some of the tests nominated for inclusion in the API compos-
ite measure were not included in the AIBL study (e.g., East
Boston Naming Test, Raven’s Progressive Matrices; [19]),
and so we were unable to construct an analogue in this data
set. It is also important to emphasize that in the present study,
we validated a composite where we removed the MMSE and
replaced it with a test of executive function.We believe that it
is important to challenge this composite with other measures
of executive function and in other cohorts to determine
whether the sensitivity of these measures can be replicated
and even improved further.
In the present study, composite scores were computed
by averaging standardized scores of each of the tests on
which they were based. Thus, all tests were weighted
equally in their contribution to the composite score. The
method of averaging standardized scores was chosen
because it had been shown to be informative by the statis-
ticians responsible for the design of the A4 trial [18].
However, given the current finding that it is possible to
improve the sensitivity of the ADCS-PACC to Ab-related
cognitive change by changing the tests on which it is
based, future studies could advance the field further by
also investigating whether improvements in the statistical
methods for combining data from different tests could
improve this sensitivity further. For example, statistical
approaches that optimize the contribution or weight of
data from individual neuropsychological tests into com-
posite scores, such as latent variable modeling or item
response theory, may increase further their sensitivity
to Ab-related change cognitive change [19,30].
Alternatively, such approaches may find a method for
retaining clinically important tests such as the MMSE in
composite scores despite their poor metric characteristics
in the sample of interest. However, we note that
Donohue et al. [18] reported that the use of optimized re-
weighting strategies did not improve the sensitivity of
their ADCS-PACC. Thus, although other approaches for
the identification of optimal composite scores should be
investigated, the current findings do provide a good start-
ing point for such challenges.
Notwithstanding these limitations, results of the pre-
sent study along with previous studies suggest that Ab-
related cognitive decline is best detected using validated
neuropsychological instruments with a particular
emphasis on the measurement of episodic memory. The
approach taken by the A4 trial in developing the
ADCS-PACC is important, as it emphasizes the charac-
terization of cognitive domains affected early in the
disease stage rather than specifying particular neuropsy-
chological tests that should be included [18]. This test-
agnostic approach allows for the construction of similar
cognitive composites and comparison and integration of
data across various research groups despite the variation
in neuropsychological tests used. Our approach to remove
Y.Y. Lim et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 19-26 25the MMSE from the ADCS-PACC and replace it with a
test of executive function (i.e., verbal fluency) rendered
this composite measure more sensitive in detecting Ab-
related cognitive decline, including in CN older adults
with different levels of high Ab burden (i.e., Ab1 CN
vs. Ab11 CN). Importantly, the current data should
not be taken to diminish the importance of the MMSE
for the identification of cognitive impairment in AD.
Rather, they indicate only that the metric characteristics
of this instrument limit its utility in understanding cogni-
tive change in the preclinical stages of AD. On a related
point, the data from the present study do not provide in-
formation about the diagnostic utility of any of the com-
posite scores for cognitive impairment. Instead, the data
indicate the extent to which they are sensitive to Ab-
related cognitive change in preclinical AD. Although
the ZAVEN composite score includes measures of the
main domains of cognitive function that are affected in
preclinical AD (i.e., episodic memory, executive function
and attention), it also pays tribute to a preeminent figure
of AD research, Dr Zaven Khachaturian. We are hopeful
that just as Dr Khachaturian has contributed substantially
to the understanding of AD, so will researchers find the
composite score we have named after him useful in un-
derstanding preclinical AD.Acknowledgments
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1. Systematic review: We conducted a review of recent
efforts to derive new cognitive composite scores that
are increasingly being relied on for large prospective
clinical trials in preclinical and early Alzheimer’s
disease (AD). This study sought to compare one
new composite score (ADCS-Preclinical Alzheimer
Cognitive Composite [ADCS-PACC]) against both
a single-domain composite score (episodic memory),
and amore theoretically derived composite score that
the authors propose (Z-scores of Attention, Verbal
fluency and Episodic memory for Non-demented
older adults [ZAVEN]), based on published litera-
ture that consistently supports the findings of early
disease-related changes in the cognitive domains of
episodic memory, attention, and executive function.
All three composite scores were compared within the
same larger prospective natural history study
(Australian Imaging, Biomarkers, and Lifestyle).
2. Interpretation: The results of our study suggest that in
cognitively normal (CN) older adults, b-amyloid
(Ab)–related decline in cognitive function is best de-
tected using validated neuropsychological instru-
ments, particularly of episodic memory. Removal
of the mini-mental state examination (MMSE)
from the ADCS-PACC and replacing it with a test of
executive function (i.e., verbal fluency) rendered it
more sensitive even to Ab-related cognitive decline
in CN older adults with only high Ab burden (i.e., CN
Ab1).
3. Future directions: Additional prospective research
should be aimed at further validating the ZAVEN
composite score for use in both clinical research
studies and clinical trials of preclinical AD. In partic-
ular, research groups that have developed cognitive
composite scores that include the MMSE or subtests
of the MMSE (e.g., the Alzheimer’s Prevention
Initiative trial) should challenge their composites
by removing the MMSE and replacing it with a test
of executive function.References
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